ResearchMoz presents professional and in-depth study of "Liquid Biopsy Market, Global Analysis by Cancer (Lung, Breast, Colorectal, etc), Products, Circulating Biomarkers, Sample, Clinical Application, Regions & Companies".
Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1866935
Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.
The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient’s tumor and provide clues about the treatment that a patient’s needs.
Renub Research report titled “Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen)” provides a complete analysis of Global Liquid Biopsy Market.
By Cancer – Lung Cancer Controls the Liquid Biopsy Market
The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market.
By Product – Majority of Liquid Biopsy Market held by Kits & Consumables
The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments.
View Complete TOC with tables & Figures @ https://www.researchmoz.us/liquid-biopsy-market-global-analysis-by-cancer-lung-breast-colorectal-etc-products-circulating-biomarkers-sample-clinical-application-regions-companies-report.html/toc
By Circulating Biomarkers
The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share
By Sample – Plasma/Serum accounts for the maximum market
In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.
By Clinical Application – Screening Purpose leads the Liquid Biopsy Market
The report studies the market of the following clinical application segments: Monitoring, Prognosis, Theranostics & Screening.
By Region – North America and Europe will drive the Liquid Biopsy Market
North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market.
Companies Analysis
Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report.
All the 9 Companies Studied in the Report have been Studied from 3 Points
Company Overview
Product Portfolio
Financial Insight
This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.
By Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Others
By Product
Kits & Consumables
Instruments
Services
By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Exosomes
By Sample
Plasma/Serum
Urine
Others
By Clinical Application
Monitoring
Prognosis
Theranostics
Screening
By Regions
North America
Europe
Asia-Pacific
Latin America
Middle East/Africa
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1866935
By Companies
Thermo Fisher Scientific Inc.
Roche Diagnostics
Bio-Rad Laboratories Inc.
Biocept Inc.
Biocartis
Myriad Genetics, Inc.
Genomic Health
NeoGenomics Laboratories
Qiagen
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1866935
Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.
The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient’s tumor and provide clues about the treatment that a patient’s needs.
Renub Research report titled “Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen)” provides a complete analysis of Global Liquid Biopsy Market.
By Cancer – Lung Cancer Controls the Liquid Biopsy Market
The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market.
By Product – Majority of Liquid Biopsy Market held by Kits & Consumables
The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments.
View Complete TOC with tables & Figures @ https://www.researchmoz.us/liquid-biopsy-market-global-analysis-by-cancer-lung-breast-colorectal-etc-products-circulating-biomarkers-sample-clinical-application-regions-companies-report.html/toc
By Circulating Biomarkers
The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share
By Sample – Plasma/Serum accounts for the maximum market
In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.
By Clinical Application – Screening Purpose leads the Liquid Biopsy Market
The report studies the market of the following clinical application segments: Monitoring, Prognosis, Theranostics & Screening.
By Region – North America and Europe will drive the Liquid Biopsy Market
North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market.
Companies Analysis
Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report.
All the 9 Companies Studied in the Report have been Studied from 3 Points
Company Overview
Product Portfolio
Financial Insight
This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.
By Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Others
By Product
Kits & Consumables
Instruments
Services
By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Exosomes
By Sample
Plasma/Serum
Urine
Others
By Clinical Application
Monitoring
Prognosis
Theranostics
Screening
By Regions
North America
Europe
Asia-Pacific
Latin America
Middle East/Africa
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1866935
By Companies
Thermo Fisher Scientific Inc.
Roche Diagnostics
Bio-Rad Laboratories Inc.
Biocept Inc.
Biocartis
Myriad Genetics, Inc.
Genomic Health
NeoGenomics Laboratories
Qiagen
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
No comments:
Post a Comment